| HOME >> MEDICINE >> TECHNOLOGY |
33.4%
$
(25,667)
35.6%Share-based compensation expense and other
(1,154)(761)(4,389)(3,495)Amortization of purchased intangibles
(1,044)(978)(2,843)(2,931)Impact of adoption of ASC 470-20
-(851)(1,251)(2,467)Levitronix Medical transaction costs
(585)-(1,144)-Return to provision true-up
(13)373(13)373Excess compensation limitations
8551,087718Levitronix fair market value inventory adjustments
(554)-(554)-Tax expense from continuing operations on a non-GAAP basis
$
(12,298)
32.9%
$
(11,451)
35.5%$
(37,836)
33.7%
$
(33,469)
35.2%The following table reconciles the guidance on a GAAP basis and non-GAAP basis from continuing operations for the periods shown below:THORATEC CORPORATIONReconciliation of GAAP to Non-GAAP Forward-Looking Guidance(Unaudited)(in thousands, except for per share data)Gross margin
For the Fiscal Year Ended 2011 Gross margin on a GAAP basis69.00%Share-based compensation expense0.50%Levitronix fair market value inventory adjustments1.00%Gross margin on a non-GAAP basis70.50%Operating expense growth
For the Fiscal Year Ended 2011 Increase in operating expense on a GAAP basis 16.00%Share-based compensation expense-1.50%Amortization of intangibles-1.10%Levitronix transaction costs-0.40% Increase in operating expense on a non-GAAP basis 13.00%Net income per diluted share reconciliation For the Fiscal Year Ended 2011 FromToNet income per diluted share on a GAAP basis
$
.08$
.12Share-based compensation expense
0.170.17Amortization of purchased intangibles
0.100.10Impact of adoption of ASC 470-20
0.030.03Levitronix fair market value inventory adjustments
0.040.04Levitronix transaction costs
0.040.04Income tax effect of non-GAAP income before tax
0.020.02Net income per diluted share on a non-GAAP basis
$<
'/>"/>
| SOURCE Thoratec Corporation Copyright©2010 PR Newswire. All rights reserved |